Clinical Pharmacology

Episodes 1-6 of 6

• • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  • 

    

    Charles P. Vega, MD

    Peer

  1

  CME/CE Broadcast Replay

  

  RestartResume

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  RestartResume

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  1.00 credits

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  1.00 credits

• • 

    

    Mark J. Alberts, MD

    Peer

  • 

    

    Matthew Jay Budoff, MD

    Peer

  • 

    

    Lawrence A. Leiter, MD

    Peer

  5

  

  RestartResume

  Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease

  RestartResume

  Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease

  0.75 credits

  Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease

  0.75 credits

• • 

    

    Javed Butler, MD, MBA, MPH

    Peer

  • 

    

    Shelley Zieroth, MD

    Peer

  9

  

  RestartResume

  High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?

  RestartResume

  High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?

  0.25 credits

  High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?

  0.25 credits

• • 

    

    Peter Libby, MD

    Peer

  • 

    

    Lawrence A. Leiter, MD

    Peer

  • 

    

    Prof. Kausik Ray, MBChB, MD, MPhil

    Peer

  5

  

  RestartResume

  Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction

  RestartResume

  Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction

  0.25 credits

  Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASC…

  0.25 credits

• • 

    

    Joseph Saseen, PharmD, BCPS, BCACP, CLS

    Peer

  • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  4

  

  RestartResume

  Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?

  RestartResume

  Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?

  0.25 credits

  Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?

  0.25 credits

• • 

    

    Lea Ann Chen, MD

    Peer

  • 

    

    Gary Lichtenstein, MD

    Peer

  9

  

  RestartResume

  Biologics for Inflammatory Bowel Disease: Maximizing Benefits, Avoiding Complications

  RestartResume

  Biologics for Inflammatory Bowel Disease: Maximizing Benefits, Avoiding Complications

  Biologics for Inflammatory Bowel Disease: Maximizing Benefits, Avoiding Complic…